A preliminary study on the association between epithelial-mesenchymal transition and circulating tumor cells in renal cell carcinoma

• Published in: Translational andrology and urology 2022-04, Vol.11 (4), p.460-471
• Main Authors: Wang, Huansheng, Li, Hao, Yuan, Yinping, Hao, Ting, Zou, Benkui, Yu, Bing, Li, Sheng, Zhang, Jianbo
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2223-4691; 2223-4683; 2223-4691
• DOI: 10.21037/tau-22-142

Circulating tumor cells (CTCs) are considered useful prognostic factors for various cancers, and in 2014, our research group conducted a comparative experiment of CTC detection in patients with renal cell cancer (RCC). However, the reason for the low detection rate of CTCs in cancer patients using the CellSearch system is still unknown, although it has been hypothesized to be attributed to the likelihood that CTCs undergoing epithelial-mesenchymal transition (EMT) do not express the CTC biomarkers cytokeratin (CK)8/18/19 or epithelial cell adhesion molecule (EpCAM). The overall aim of the current study was to investigate the expression levels of CK8/18/19 and EpCAM in relation to the EMT biomarkers vimentin and E-cadherin in patients with RCC. Patients with RCC who had undergone radical nephrectomy or partial resection between May 2014 and December 2014 were initially recruited. Among 34 RCC patients, nine co-expressed EpCAM and CK8/18/19 in primary tumor tissues. The CellSearch results showed that CK8/18/19 was expressed in 5 of 6 patients (5/6) and EpCAM was expressed in 6 patients (6/6). However, the isolation by size of tumor cells (ISET) technique showed these were co-expressed in only four of the 10. The expression of CK8/18/19, EpCAM, vimentin, and E-cadherin was distributed unequally in different enumeration groups of CTCs (all P>0.05), and the positive expression of CK8/18/19 was correlated with neutrophil number and tumor size (P